![Dear Freddie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dear Freddie
Investitore di Private Equity presso Monograph Capital Advisors (UK) LLP
Posizioni attive di Dear Freddie
Società | Posizione | Inizio | Fine |
---|---|---|---|
Monograph Capital Advisors (UK) LLP
![]() Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | Investitore di Private Equity | 01/12/2021 | - |
Ascend Gene & Cell Therapies Ltd.
![]() Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | Corporate Officer/Principal | 01/12/2021 | - |
Storia della carriera di Dear Freddie
Precedenti posizioni note di Dear Freddie
Società | Posizione | Inizio | Fine |
---|---|---|---|
Syncona Partners LLP
![]() Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investitore di Private Equity | 01/02/2018 | 31/12/2021 |
Quell Therapeutics Ltd.
![]() Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Direttore operativo | 01/04/2019 | 31/03/2020 |
Formazione di Dear Freddie
The University of Edinburgh | Undergraduate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 6 |
Posizioni
Private Equity Investor | 2 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Settori
Finance | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Syncona Partners LLP
![]() Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Monograph Capital Advisors (UK) LLP
![]() Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | Finance |
Ascend Gene & Cell Therapies Ltd.
![]() Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | Commercial Services |
Quell Therapeutics Ltd.
![]() Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Dear Freddie
- Esperienza